申联生物: 第四届监事会第四次会议决议公告

Group 1 - The core viewpoint of the announcement is that the Supervisory Board of the company has reviewed and approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results for the first half of 2025 [1][2] - The Supervisory Board unanimously agreed that the preparation and review procedures of the semi-annual report comply with relevant laws and regulations, and there are no false records or misleading statements [2] - The company has completed the investment projects funded by the initial public offering, and the special account for raised funds has been closed, ensuring compliance with regulations regarding the use of raised funds [2][3] Group 2 - The Supervisory Board has proposed to cancel the Supervisory Board as part of a decision to enhance the company's governance structure, which aligns with the latest legal requirements and the company's operational needs [3][4] - The cancellation of the Supervisory Board will not harm the interests of shareholders, particularly minority shareholders, and the responsibilities of the Supervisory Board will be transferred to the Audit Committee of the Board of Directors [3][4] - This proposal is subject to approval at the company's shareholders' meeting, and until then, the current Supervisory Board will continue to fulfill its supervisory duties diligently [4]